心力衰竭生物标志物是否影响心力衰竭治疗反应?
Tiffany Yuen1, Pishoy Gouda1, Robert Margaryan2
1Division of Cardiology, University of Alberta, Edmonton, Canada.
Current heart failure reports
|September 7, 2023
概括
心力衰竭 (HF) 生物标志物对于诊断和预后至关重要. 未来的研究旨在利用这些生物标志物来个性化HF治疗,并监测患者对治疗的反应.
科学领域:
- 心脏病学 心脏病学
- 生物标志物发现发现
- 翻译医学是一种翻译医学.
背景情况:
- 心力衰竭 (HF) 对全球心脏病发病率和死亡率作出了重大贡献.
- 了解高频细胞和分子通路的进步已经确定了许多生物标志物.
- 酸是已知用于诊断和预后的HF生物标志物.
研究的目的:
- 审查当前的高频生物标志物的现状.
- 确定具有潜在指导和监测HF治疗反应的新生物标志物.
- 探索生物标志物在诊断和预后之外的不断变化的作用.
主要方法:
- 对当前高频生物标志物研究的文献综述.
- 对已建立和新兴的高频生物标志物的分析.
- 对指导和监测HF治疗中的生物标志物实用性的评估.
主要成果:
- 已经确定了许多高频生物标志物,但它们在指导治疗中的有效性仍在研究中.
- 已确立的生物标志物,如性尿素,对于HF诊断和预后至关重要.
- 新兴的生物标志物显示出个性化HF治疗和监测治疗反应的前景.
结论:
- 生物标志物是控制心力衰竭的重要工具.
- 需要进一步的研究来验证指导药理疗法的新生物标志物.
- 生物标志物指导治疗有可能为HF患者提供个性化治疗策略.
相关概念视频
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure Drugs: β-Blockers
363
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
363
Heart Failure VII: Nursing Interventions
90
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
90
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460


